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Abstract: This review article provides a perspective on the synthesis of alicyclic and heterocyclic
ring-fused benzimidazoles, imidazo[4,5-f ]benzimidazoles, and imidazo[5,4-f ]benzimidazoles. These
heterocycles have a plethora of biological activities with the iminoquinone and quinone derivatives
displaying potent bioreductive antitumor activity. Synthesis is categorized according to the cycliza-
tion reaction and mechanisms are detailed. Nitrobenzene reduction, cyclization of aryl amidines,
lactams and isothiocyanates are described. Protocols include condensation, cross-dehydrogenative
coupling with transition metal catalysis, annulation onto benzimidazole, often using CuI-catalysis,
and radical cyclization with homolytic aromatic substitution. Many oxidative transformations are
under metal-free conditions, including using thermal, photochemical, and electrochemical methods.
Syntheses of diazole analogues of mitomycin C derivatives are described. Traditional oxidations of
o-(cycloamino)anilines using peroxides in acid via the t-amino effect remain popular.
Keywords: green chemistry; halogen; heterocycle; hydrogen peroxide; imidazole; iodine; nitrosoben-
zene; oxone; palladium; quinone
1. Introduction
1.1. Significance and Biological Activity
Benzimidazole is an important heterocyclic pharmacophore. Therapeutic interest was
aroused in the 1950s, when 5,6-dimethylbenzimidazole was discovered as a degradation
product of vitamin-B12 (Figure 1) [1,2]. Benzimidazoles possess a wide range of biolog-
ical activities [3–6], significantly utilized as APIs in medicines [5], and as pesticides [6].
Moreover among the ring-fused benzimidazoles, pyrimido[1,2-a]benzimidazoles were
discovered as effective corticotropin releasing factor-1 (CRF-1) receptor antagonists for
potential treatment of mental health disorders [7]. A pyrrolo[1,2-a]benzimidazole was
found to be the most effective cyclin-dependent kinase 4/6 (CDK4/6) inhibitor evalu-
ated within a series of highly functionalized five to seven-membered alicyclic ring-fused
benzimidazoles [8]. Other ring-fused benzimidazoles, the imidazobenzodiazepines were
investigated as poly(ADP-ribose) polymerase (PARP-1) inhibitors, allowing reduction of
hyperglycemia with neuroprotective effects in animal models [9].
The most widely studied of the applications of ring-fused benzimidazoles and imi-
dazobenzimidazoles is as bioreductive antitumor agents, when the fused benzene part is
an iminoquinone or quinone functionality (Figures 2–5). Indole-based natural products
often inspire analogue synthesis, including imidazoquinoxalinone analogues of the marine
natural product, wakayin [10], a topoisomerase I inhibitor (Figure 2).
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Figure 1. Benzimidazole in vitamin B12 and biologically-active ring-fused systems [1–9]. 
 
Figure 2. Imidazole-based wakayin analogues [10]. 
Mitomycin C (MMC) has, however, attracted most interest, as the archetypal biore-
ductive antitumor antibiotic, which cross-links to DNA [11]. Incorporation of the DNA-
alkylating aziridinyl moiety leads to cytotoxicity via the FANC DNA-repair pathway 
[12,13], and the benzimidazole analogue of the bioactivated form of MMC (aziridinomi-
tosene) was prepared and evaluated against breast cancer cell lines [14] (Figure 3). Skibo 
has published extensively on aziridinylpyrrolo[1,2-a]benzimidazolequinones (PBIs) as 
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Figure 3. Aziridinyl-functionalized antitumor agents [11–18]. 
One or two-electron reductases are responsible for bioreductive activation. NADPH-
cytochrome c (P450) reductase is predominant under hypoxic conditions with the one-
electron reduction reversed by oxygen [19]. Many solid tumors also over-express the ob-
ligatory two-electron reductase NAD(P)H:quinone oxidoreductase 1 (NQO1, also known 
as DT-diaphorase), which is a popular target for anti-cancer studies [20]. Many anti-cancer 
agents do not contain conventional DNA damaging functionality, and cytotoxicity may 
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agents do not contain conventional DNA damaging functionality, and cytotoxicity may
be due to the formation of reactive oxygen species. Pyrido[1,2-a]benzimidazolequinone 1
(Figure 4) is more than 300 times more cytotoxic under hypoxic conditions than the clinical
drug, MMC (Figure 3), with cytotoxicity for alicyclic ring-fused benzimidazoles correlated
to reductive potentials [21,22]. Highly conjugated naphthyl fused benzimidazolequinone 2
leads to increased stability of reduced intermediates leading to specificity towards human
cancer cell lines over-expressing NQO1 [23].
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brevity, full papers are cited and not the preceding communication article. A historical 
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Ring-fused imidazo[4,5-f ]benzimidazolequinones 3a and 3b are NQO1 substrates [24,25],
with 3a, at the National Cancer Institute (NCI), showing specificity towards the killing of
melanoma cell lines (Figure 5) [24]. Our group was the first to provide viable synthetic
protocols for accessing ring-fused imidazo[5,4-f ]benzimidazoles, enabling evaluation of
quinone and iminoquinone derivatives for toxicity against cancer cell lines [26–29]. Com-
pared to alicyclic ring-fused analogues 4a and 4b, the oxygen atom of the 1,4-oxazino ring
was found to increase toxicity of 4c [27]. Iminoquinone 5a isolated from the Fremy oxida-
tion to prepare 4b, was unexpectedly the most potent imidazobenzimidazole, with more
than 12 times greater cytotoxicity towards a prostate cancer cell line (DU145) than a normal
fibroblast cell line (GM00637) [26]. More intensive cytotoxicity assays, computational
docking, and NCI COMPARE analysis on 5a, revealed good correlation with NQO1 [28].
In contrast, isomeric imidazo[4,5-f ]benzimidazole 5b was inactive against the NCI 60 cell
line panel [29].
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1.2. Available Synthetic Methods
The categories of syntheses of ring-fused benzimidazoles 6 are according to the cy-
clization reaction (Scheme 1). Oxidative cyclizations from aniline or anilide derivatives is
the most studied route (Route A) and is presented in context with the plethora of other
syntheses that build the benzimidazole moiety (Routes B–D). The section on Route A is
sub-divided into syntheses of benzimidazole and imidazobenzimidazole scaffolds. Lastly,
there is a section on syntheses, which begin with the benzimidazole moiety (Route E),
sub-divided according to reaction (type) conditions. This is not an exhaustive review, and
the reader should consult reviews on polycyclic benzimidazoles for comprehensive lists of
syntheses [30–33]. Since the late 1990s, Aldabbagh et al. have worked on the discovery of
new ring-fused benzimidazoles and synthetic methods, and the collated articles related
to their research are reviewed herein. A reviewer recommended a Scifindern search of
“benzimidazole-fused”, which was completed, and significant references are incorporated.
For brevity, full papers are cited and not the preceding communication article. A historical
perceptive is taken and analysis of the most significant contributions to the field is carried
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out. In particular, methodology that forms a variety of ring-fused benzimidazoles is of
interest, rather than procedures that give mainly the benzimidazole core.
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2. Syntheses of Ring-Fused Benzimidazoles and Imidazobenzimidazoles
2.1. Oxidations of o-Cycloaminoanilines and Anilide Derivatives (Route A)
There are distinct differences in the reaction mechanisms and conditions for ring-fused
benzimidazole and imidazobenzimidazole formation warranting sub-division. Benzim-
idazoles form by oxidative cyclization of anilines via nitrosobenzene intermediates; in
contrast, cyclization to give the ring-fused imidazobenzimidazole must begin from anilides
and proceed via amine N-oxide intermediates under acidic conditions.
2.1.1. Forming Ring-Fused Benzimidazoles
In 1908, Spiegel and Kaufmann reported that Caro’s acid (peroxymonosulfuric acid,
H2SO5) oxidized 5-nitro-2-(piperidin-1-yl)aniline to 7-nitro-1,2,3,4-tetrahydropyrido[1,2-
a]benzimidazole [34]. In the absence of the nitro-substituent, no oxidative cyclization
occurred. Caro’s acid was already known to oxidize anilines to nitrosobenzenes [35], so
supporting the idea of a nitroso intermediate. The prominent 20th century chemist and
creator of Adam’s catalyst, Roger Adams with Nair refined this methodology, and accessed
a range of five to seven-membered ring-fused benzimidazoles in good to high yields us-
ing peroxytrifluoroacetic acid generated in situ from H2O2 and trifluoroacetic acid (TFA)
(Scheme 2) [36]. Six-membered cyclization yields were higher, when the anilines contained
a nitro-substituent. Meth-Cohn and Suschitzky [37] soon refuted the observation made
by Nair and Adams that acyl derivatives do not undergo cyclization to give benzimida-
zoles. These workers showed a range of anilide derivatives (formyl, acetyl and benzoyl)
underwent oxidative cyclizations using peroxytrifluoroacetic acid or performic acid (H2O2
and HCO2H). Meth-Cohn preferred the se of o-cyclic amine substituted anilides as sub-
strates for making ring-fused benzimidazoles [37,38]. Meth-Coh comment that Nair
and Adams [36] h d possibly formed the anilide in situ, due to the initial additio of TFA
followed by H2O2 [38]. Mechanisms were propose for benzimidazole formation from
anilide, via an amine-N-oxide rather than the nitroso intermediate (see Section 2.1.2). L ter
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the use of anilide derivatives as substrates for preparation of ring-fused benzimidazoles
would become commonplace (Scheme 3) [13,15,27,37–40].
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Significant a ounts of seven- and eight- e bered ring-fused [1,2-a]benzimidazoles
9a and 9b ere for ed fro nitrobenzenes 7a and 7b during the one-pot catalytic hy-
drogenation and acetylation to give acetamides 8a and 8b (Scheme 3a) [39]. It seemed
that the conformation of these large alicyclic rings favored advantageous cyclization of
nitroso intermediates formed during the hydrogenation process. Acetamides 8a and 8b
were cyclized using performic acid to 9a and 9b in good yields, with the former trans-
formed to 3-aziridinylazepino[1,2-a]benzimidazolequinone [13,39]. A readily available
and safer alternative to Caro’s acid is Oxone (2KHSO5·KHSO4·K2SO4) [41]. Due to the
absence of organic waste products, Oxone in the presence of formic acid gives ring-fused
benzimidazole [27,40] and imidazobenzimidazole [27] adducts without the requirement for
chromatography. 2-Oxa-7-azaspiro[3.5]nonane acetamide 10 gave the spirocyclic oxetane
ring-fused benzimidazole 11 in good yield by simple organic extraction from the basified
aqueous mixture (Scheme 3b) [40].
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Scheme 3. cetanilide cyclizations onto (a) azepino- and azocino- [39], and (b) spirocyclic oxetane-
[40] derivatives.
Preparations of ring-fused benzimidazoles using o-cyclic amine substituted anilines
with performic acid compare favorably with the derivat e anilide reaction, with Smalley et al.
r porting moderate to good yields for five- to seven-m mbered adducts (Scheme 4a) [42]. In
a more recent study, recyclable ethyl ac tate (EtOAc) replaced formi acid, with aqueous
effl nt, organic-aqueous extraction and hromatography avoided for the preparation of
pyrrolo[1,2-a]benzimidazoles from comm rcial o-(pyrrolidin-1-yl)anilines (Scheme 4b) [43].
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Although, the presence of strong electron-withdrawing substituents (NO2, CN) and the
six-membered cyclization required methanesulfonic acid (MsOH) to reach high yields.
However, MsOH is a green acid undergoing biodegradation by forming CO2 and sul-
fate [44].
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Scheme 7. The al oxidative y lizations mediated by (a) TEMPO/
Aniodic oxidatio gave the required i ini io 14 for cyclizatio (Sc e e 8) [51].
The electrolyte was n-Bu4 PF ( l ), an the anode is reticulated vitreous carbon
(RVC), and Pt is the cathode in an undivided cell at a constant current of 10 mA. A Russian
team reported the electrochemical oxidative cyclization with reduction of nitrobenzene for
cyclization onto an o-piperidinyl-substituent to give pyrido[1,2-a]benzimidazoles [52].
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More recently, we heralded the use of H2O with hydrohalic acid (HX), as a convenient
oxidizing and halogenation system for organic synthesis [54–56]. The system allows in
situ generation of Cl2 and Br2, with the only by-product, being water (Scheme 10). The
salt of hypochlorous acid (HOCl) is the active ingredient in domestic bleach and is the
intermediate of the reaction between H2O2 and HCl.
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o estic bleach gave cyclization and dichlorination of anili e 15 in 56% yield (Scheme 11a),
with the lower yield attributed to the requirement for chromatography to separate the ad-
ditives in the bleach [54]. Moreover, using H2O2/HX a library of selectively dichlorinated
and dibrominated ring-fused benzimidazoles was prepared in high yields from commer-
cial o-cyclic amine substituted anilines, with most cases not requiring chromatography
(Scheme 11b,c). 5-Fluoro-2-piperidinylaniline was an exception, giving significant amounts
of cyclization with monochlorination or monobromination. Bromination tended to be
slower than chlorination, and tribrominated product 16 was isolated for the o-(pyrrolidin-
Molecules 2021, 26, 2684 9 of 29
1-yl)aniline, due to difficulties in cleanly isolating 5,7-dibromopyrrolo[1,2-a]benzimidazole
(Scheme 11d).
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Scheme 11. One-pot ring closure with selectiv halogenation using (a) domestic bleach or H2O2/HCl, (b) H2O2/HCl, and
(c) H2O2/HBr, and (d) five to eight-membered ring-fused adducts [54].
3,6-Dimethoxy-2-(cyc oamino)anilines underwent 6-electron xidations to afford a
variety of ring-fused halogenated benzimidazolequi ones, when using higher amounts of
HCl or HBr relative to H2O2 (Scheme 12 ) [55]. The active species is the e emental halogen
(X2) with water equired for quin e formation (Scheme 12b). When less in situ halogen
was ge erated, using [H2O2] > [HX], the 4-electron oxidation occurred, to give ring-fused
halogenated benzimidazoles (Scheme 12c).
The use of hydroiodic acid (HI) is pr ferre wh n oxid tive cyclization is required
without halogenation [56], due to the relatively smaller electrophilicity of iodine [57]. Five-
and seven-membered cyclizations of 3,6-dimethoxy-2-(cycloamino)anilines with H2O2
and a catalytic amount of HI in EtOAc proceeded in high yield (Scheme 13a), but 1,4,6,9-
tetramethoxyphenazine 17, was unexpectedly formed, as an orange precipitate from six-
membered cyclizations (Scheme 13a,b) [56]. The absence of phenazine 17 from the five- and
seven-membered cyclizations was consistent with previous observations that six-membered
oxidative cyclizations are more difficult [36,43]. The formation of 17 was optimized by
reducing the amount of EtOAc (the reaction solvent) by four-fold and by decreasing the
reaction temperature to room temperature (Scheme 14). Moreover, the isolation of 17 was
indicative of a nitrosobenzene intermediate in the conversion of o-(cycloamino)anilines to
Molecules 2021, 26, 2684 10 of 29
ring-fused benzimidazoles via the so-called t-amino effect [58]. Syntheses of phenazines
involve nitroso intermediates [56,59,60]. Recent evidence in the synthesis of ring-fused
benzimidazoles, included GC-MS of the reaction mixture (Scheme 14), after 1 h, which
revealed EI-MS fragmentation pattern consistent with intermediate 18 [56].
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The diamine-N-oxide intermediate 26 for imidazo[5,4-f ]benzimidazole f rmation was
isolated by Fagan [27]. The X-ray crystal structure of 26 showed hydrogen bonding between
th amide NH an the ami e N-oxide residues, supporting the abse ce of the amide NH
peaks in the 1H NMR sp ctra of solutions f amine N- xides [27,38,61]. T is is contrary to
the orientation of the amine-N-oxide 25 adopte in Meth-Cohn’s Polonovski-type reaction
Molecules 2021, 26, 2684 14 of 29
mechanism [38]. Our proposed mechanism begins with oxidation of the cyclic amines of di-
acetamide 27 to the Fagan amine-N-oxide orientation 26 (Scheme 18). Protonation in acidic
media gives the imidols, upon loss of water. The double intramolecular nucleophilic imidol
addition onto the iminum ion leads to the ring-fused imidazo[5,4-f ]benzimidazole [27].
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An a id-catalyzed cyclization mechani m was propo ed f r conversi n of dimorpho-
line N-oxide 26 to the [1,4]oxazino[4,3-a]b nzimidazole (Scheme 19a) [27]. In the absence of
an external oxidant, oxidation is possible through the internal conjugated system. MsOH
allowed conversion of amine N-oxide 28 to the imidazo[4,5-f ]benzimidazole, where pre-
sumably another molecule of 28 acts as oxidant (Scheme 19b) [61].
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2.2. Reductions of Nitrobenzene-o-Cycloamines (Route B)
The reduction under acidic conditions of the aromatic nitro-group with cyclization
onto the adjacent cycloamine substituent dates to the 1960s and employ ZnCl2/Ac2O [16,
64,65], TiCl3/HCl [66], and Fe/AcOH [67]. There are cyclizations using Pd-catalysis with
CO [68] or H2 [69]. Recent metal-free conditions use visible light, phenylthiourea as catalyst
and PhSiH3 as reductant [70], and electrochemical cyclizations [52]. Thermal annulation
using nitrobenzene substrates are possible with neat 1,2,3,4-tetrahydroisoquinoline (THIQ)
(Scheme 20a) [71], and cyclizations occur using I2/HCO2H [72] (Scheme 20b). For the
former reaction, the authors speculated on THIQ acting as a hydride donor after the initial
SNAr and redox cyclization, while HI generated in situ, is the active catalytic species in the
latter reaction, acting as a strong Brønsted acid and reductant [71,72].
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2.3. Using Aromatic Amidines, Lactams, and Isothiocyanates (Route C)
Non-redox cyclizations of o-haloarylamidines give ring-fused benzimidazoles, using
CuI as catalyst [73,74] (Scheme 21a) or strong base (Scheme 21b) [8,75], where nitrogen
displaces the o-halogen. Pyrrolo[1,2-a]benzimidazole was reported from an o-lactam substi-
tuted aniline cyclization using di-t-butyl sulfoxide/NBS via an aza-Wittig type-reaction
(Scheme 21b) [76]. 1-(2-Isothiocyanatophenyl)pyrrolidines cyclize under thermal acidic
conditions to benzimidazothiazepines (Scheme 21c) [77].
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Scheme 21. Synthesis from (a) o-haloarylamidine [75], (b) a lactam derivative of o-phenyldiamine [76],
and (c) a rearrangement of aryl isothiocyanates [77].
Hypervalent iodine(III) reagents allow cyclization of aryl amidines onto non-functionalized
benzenes (leaving group = H) [78,79]. The overall dehydrogenative process is proposed to
proceed via a homolytic aromatic substitution (HAS) of nitrogen-centered radicals giving
pyrrolo- and pyrido[1,2-a]benzimidazoles (Scheme 22a) [78]. Kosher’s reagent (PhI(OH)OTs)
Molecules 2021, 26, 2684 16 of 29
gave a range of thiazino and oxazino ring-fused benzimidazoles (Scheme 22b) [79]. The
oxazino ring-fused benzimidazole required a longer reaction time, and the use of 4Å
molecular sieves.
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This includes the traditional bimolecular condensation of 1,2-phenylenediamines 
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tion intermediate [83].  
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A combination of Chan−Lam and Ullmann type couplings were said to give the fully
unsaturated pyrido[1,2-a]benzimidazol s using 2-aminopyridine and 2-iodoarylboronic
acids via an amidine intermediate (Scheme 23) [80].
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Scheme 23. Synthesis of pyrido[1,2-a] benzimidazoles via amidine intermediates [80].
2.4. Condensations (Route D)
This includes the traditional bimolecular condensation of 1,2-phenylenediamines with
aldehydes (Scheme 24) [81,82]. Rh-catalyzed cyclization of N-alkenyl-1,2-diaminobenzenes
with CO/H2 gas gave alicyclic ring-fused benzimidazoles via a hydrofor ylation interme-
diate [83].
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A Pd-catalyzed reductive cyclization gave a variety of benzimidazole-fused thia-
zocine scaffolds (Scheme 32), but also thiazonines (9-membered rings), and thiazecines
(10-membered) having an exocyclic double bond [99]. Ammonium formate is the hydrogen-
donor.
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lations of imidazobenzimidazole using 1-chlorobutane and 1-chloro-4-(phenylselenyl)butane.
For Bu3SnH-mediated reactions, slow addition of radical initiators is required, which pre-
vents Bu3SnH reduction of the cyclizing radical. Camphorsulfonic acid (CSA) or Ac2O are
added to more difficult cyclizations, to activate the benzimidazole-2-position towards nucle-
ophilic radical addition [21,26]. For the HAS onto imidazobenzimidazoles (Scheme 34b,c),
exposing the reaction mixture to air for part of the reaction time gave higher yields, since
oxygenated radicals are thought to be involved in the oxidative re-aromatization (or hydro-
gen atom-abstraction) step [26,108].
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n alternative approach to S, is initiator-free, using in situ generated Barton ester
inter ediates derived from robust and readily accessible carboxylic a id substra es, giving
five- to seven-memb red alkyl and cyclopropyl radic l cyclizations via a ch in reaction
mechanism (Scheme 33b) [104,109]. Most recently, benzimidazo[2,1-a]is quinolin-6-ones were
prepared by the ddition of methyl radicals onto N-methacryloyl-2-p enylbenzimidazoles 30
using di-tert-butyl perox d (DTBP) initiator (Scheme 35) [110]. The tertiary adduct radical
undergoes six-membere cyclization followed b oxidation of the erived cyclized radical.
Earlier, tert-butyl radicals generated from pivalic acid and several other carboxylic acids
with K2S2O8/AgNO3 initiated an analogous casca e [111].
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using hypervalent iodine(III) reagents and elemental iodine under metal-free conditions.
There is an increasing use of sustainable and non-metal-mediated protocols, including
photochemical, electrochemical, and thermal methods. Mild oxidative conditions tend to
be more effective for preparing isoindoline and tetrahydroisoquinoline-fused scaffolds.
There are effective methods for incorporating heteroatoms into the fused-ring, including
N, O, and S atoms, and forming alicyclic rings with additional fused cyclopropane or
delicate oxetane and aziridine rings. In terms of versatility, green chemistry, and value
for money, it is difficult to beat the use of H2O2 in traditional oxidative cyclizations of o-
(cycloamino)anilines. H2O2 in combination with HX generates the ordinarily inconvenient
elemental halogen (X2) in situ, to mediate one-pot oxidative cyclization with halogenation.
The latter includes one-pot approaches to potential antitumor ring-fused benzimidazole-
quinones from readily accessible anilines. Oxone is a cheap alternative, with technical and
environmental benefits, including the circumvention of organic waste by-products. Our
present work generates X2 in situ, by combining Oxone with benign NaX, to carry out one-
pot halogenation with oxidative demethylation to give the dimeric quinones of ring-fused
dimethoxybenzimidazole-benzimidazolequinones (DMBBQs) [118]. The DMBBQ scaffold
offers unique regioselective functionalization opportunities for bis-quinone motifs, and
these unique dimeric structures require investigation as bioreductive anti-tumor agents.
Mechanisms for ring-fused benzimidazole and imidazobenzimidazole formation via
the t-amino effect are now better defined. Recent studies have shown that acid and
heat are unnecessary for oxidative cyclization via a nitrosobenzene intermediate using
o-(cycloamino)anilines as substrates for benzimidazole formation. This offers opportunities
for further investigations into the synthesis of ring-fused benzimidazoles under nonag-
gressive ambient conditions using commercial anilines as starting materials. While use of
anilide derivatives results in a different mechanism via an amine-N-oxide intermediate.
The anilide derivative and acidic conditions are mandatory for peroxide-mediated ring-
fused imidazobenzimidazole preparations. To date ring-fused imidazobenzimidazoles
have only been prepared via oxidative cyclizations of anilides and radical cyclizations
onto imidazobenzimidazoles, surely new synthetic methods will merge for this interesting
scaffold.
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